Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Getting prolactin levels under control isn't the whole story. A new Dutch study of 450 women with prolactinoma found that fatigue and concentration problems persisted even in those with biochemically controlled disease. Anxiety and depression were also notably common, affecting nearly a third of women in remission — signaling that treatment success needs a broader definition.
Normalizing prolactin levels may be the clinical benchmark, but it's far from the finish line for many women with prolactinoma. A large Dutch multicenter study published in The Journal of Clinical Endocrinology & Metabolism found that fatigue and cognitive complaints remained highly prevalent even in women whose disease was biochemically controlled — raising important questions about how treatment success is defined.
The cross-sectional analysis included 450 women (median age 36.4 years), split between those with active disease and those with controlled disease (on dopamine agonists or in remission). While controlled disease was associated with better quality of life and lower anxiety and depression scores, symptoms like fatigue, concentration problems, and even galactorrhea didn't fully resolve.
By the Numbers:
Why it matters: These findings highlight a significant unmet need — biochemical control alone isn't enough. Clinicians should consider psychological and cognitive rehabilitation as part of comprehensive prolactinoma management, especially in younger women.
